Open Access

Finerenone in reducing mortality and morbidity in diabetic kidney disease

Congress Session

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)
55 presentations
1 follower

3 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Mineralcorticoid-antagonists in chronic kidney disease and Type 2 Diabetes: Key clinical findings from current studies.

Speaker: Professor R. Schmieder (Erlangen, DE)

Thumbnail

Discussion and closure.

Thumbnail

Access the full session

Improving cardiovascular and renal outcomes in diabetic kidney disease

Speakers: Professor G. Filippatos, Professor S. Anker, Professor R. Schmieder
Thumbnail

About the event

Image

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Related content

Open Access

An asymptomatic patient with positive treadmill test during screening for life insurance and significant proximal LAD disease in coronary CT angiography: what do the guidelines say?

27 August 2021

Open Access

The ECG and beyond: artificial intelligence will penetrate cardiology practice.

27 August 2021

Open Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk